SUMMARY AT A GLANCE
IgA nephropathy is a major cause of CKD in the world. Using of new biomarkers, we should select the treatment for the patients with IgA nephropathy.
ABSTRACT:
Chronic kidney disease has become a worldwide problem. Among chronic kidney disease patients, IgA nephropathy is common in the world. Serum levels of galactose deficient (Gd)-IgA1 and Gd-IgA1-specific antibodies are elevated in most IgA nephropathy patients. Glomerular Gd-IgA1 deposition has been observed by immunofluorescence. There are many reports that the anti-proteinuric effect is significantly greater in groups who receive tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Furthermore, patients with tonsillectomy with steroid pulse therapy have shown a strong down-regulation of delta serum IgA/C3 per year and have conserved their renal function. New treatments, that is, Atacicept and glucocorticoid budesonide, have been developed for this disease.
CHRONIC KIDNEY DISEASE
Chronic kidney disease (CKD) patients have been shown to have: (i) a risk in the loss of kidney function; (ii) risks for cardiovascular disease, mortality and hospitalization and (iii) relevant financial problems. As in the report from the Japanese Society of Nephrology (JSN), 13.0 million people in Japan have CKD. Major causal diseases are diabetic kidney disease, chronic glomerulonephritis (mainly IgA nephropathy), hypertensive nephrosclerosis and polycystic kidney disease in Japan. About 40-60% of patients with chronic glomerulonephritis are diagnosed as having IgA nephropathy by renal biopsy. Gd-IgA1-specific antibodies are significantly elevated in most IgA nephropathy patients. It appears that a panel of these above mentioned biomarkers may be helpful in differentiating IgA nephropathy from other glomerular diseases. 4 Many researchers have examined the levels of serum GdIgA1 using a snail Helix aspersa agglutinin (HAA) lectinbased assay, but found that this assay has some problems. Yasutake et al. 5 aimed to establish a more robust and stable enzyme-linked immunosorbent assay (ELISA) utilizing a specific monoclonal antibody to recognize the hinge region in human Gd-IgA1. Levels of serum Gd-IgA1 measured by Gd-IgA1 ELISA in IgA nephropathy patients were significantly increased compared with those in patients with other renal diseases or non-renal diseases. Recently, an antihuman Gd-IgA1 rat IgG monoclonal antibody (KM55) has been newly released by IBL-Japan (http://www.ibl-japan.co. jp) and therefore, we are now able to measure the levels of serum Gd-IgA1 using Gd-IgA1 ELISA (Code No. 27600). In immunofluorescence using KM55, Gd-IgA1 in glomeruli colocalized with IgA ( Fig. 1 ). These methods using KM55 are useful for the diagnosis of IgA nephropathy.
PATHOGENESIS OF IGA NEPHROPATHY

The serum IgA/C3 ratio
The authors have already reported that the serum IgA/C3 ratio was an important clinical marker in IgA nephropathy prior to renal biopsy. 6 There are many reports on tonsillectomy with steroid pulse (TSP) therapy in IgA nephropathy patients. The patients with TSP therapy showed a strong down regulation of delta (Δ) serum IgA/C3 per year and conserved their renal function. Shimizu et al. 7 We have usually prescribed for IgA nephropathy patients according to the recommended grade of the Evidence-based Clinical Practice Guideline for CKD patients in Japan (JSN, 2013, article in Japanese). 8 Recommended grades are divided into five levels, that is, A (Implementation in routine clinical practice is strongly recommended due to sufficient evidence), B (Implementation in routine clinical practice is recommended because of the existence of some evidence), C1 (Implementation in routine clinical practice may be recommended despite insufficient evidence), C2 (Implementation in routine clinical practice is not recommended due to insufficient evidence) and D (Implementation in routine clinical practice is not recommended because of evidence that it might be harmful to patients). 8 There are many therapeutic strategies, as follows:
(i) adequate aerobic exercise and a low-protein diet.
(ii) Anti-platelet drugs (dipyridamole and dilazep hydrochloride) are recommendation Grade C1. (iii) Anti-hypertensive drugs: (a) RAAS inhibitors angiotensin II receptor blocker 
KDIGO clinical guideline for glomerulonephritis
The suggestion of corticosteroids + renin angiotensin aldosterone system (RAAS) inhibitors has been reported in this guideline. 9 First, we control blood pressure and proteinuria using RAAS inhibitors and then added corticosteroids. These drugs reduced the levels of urinary protein excretion and preserved renal function in patients with IgA nephropathy. Kidney disease improving global outcome (KDIGO) discussed this guideline in Singapore last year and will revise it soon. However, recent reports have shown that oral corticosteroid therapy was associated with an increased risk of serious adverse events, such as infections.
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Tonsillectomy and steroid pulse therapy
In Japan, TSP therapy is very common (in internal medicine, 61.4% and in paediatrics, 68.9%) 11 and is more effective for patients with IgA nephropathy. 12, 13 According to the protocol for TSP therapy, that is, Pozzi's method, the effect on haematuria (Japanese Remission Criteria: −, AE or <5 red blood cells (RBCs)/HPF for >6 months) was 69.0% and that on proteinuria (Japanese Remission Criteria: −, AE, or <0.3 g/day or 0.3 g/gCr for >6 months) was 67.3% in the Juntendo University Hospital. 14 Since macroscopic haematuria is frequently observed after upper respiratory tract infections in IgA nephropathy patients, the relationship between tonsillar infection and IgA nephropathy has been intensely discussed. The tonsils are mucosal lymphatic organs, and polymeric IgA1 is produced on their mucosal membrane, with some of this polymeric IgA1 considered as nephritogenic. Plasma cells producing circulating nephritogenic polymeric IgA1 and glomerular deposited immune-complexes are suggested to form there. Theoretically, TSP may effectively eradicate the plasma cells producing nephritogenic IgA1 in the tonsils and prevent the cells from transferring to the bone marrow. 15 Nakata et al. 16 indicated the palatine tonsils are probably a major site of Gd-IgA1-producing cells. However, in some patients, such specific cells may have already propagated to other lymphoid organs long before TSP, and this may partially explain the different responses. In a multicentre randomized controlled trial (RCT), Kawamura et al. 17 reported that the anti-proteinuric effect was significantly greater in the group who received TSP therapy in patients with IgA nephropathy. The results of recent meta-analysis of TSP therapy showed clinical remission in this disease. 18 The effects of TSP therapy still need to be determined from other RCT in the future since TSP therapy has not been internationally accepted by nephrologists.
New treatments
Atacicept
Stalk-1 specifically recognizes a proliferation-inducing ligand (APRIL) producing cells. In immunohistochemistry, stalk-1 positive cells in human tonsillar germinal centres (GC) were observed in patients with IgA nephropathy. Percentages of stalk-positive GC in the tonsils in this disease are significantly higher than those in chronic tonsillitis patients as controls. The relationship between the B cells in the GC and the production of glycan-specific antibodies was observed in patients with IgA nephropathy. 
Glucocorticoid budesonide
In 2011, Smerud et al. 20 studied the efficacy and safety of a new enteric formula of the locally acting glucocorticoid budesonide, which was designed to release its active compound in the ileocecal region. This enteric budesonide had a significant effect on urinary albumin excretion, along with a minor reduction of serum creatinine and a modest increase of estimated glomerular filtration rate (eGFR). A targeted-release (TRF)-budesonide of 16 mg/ day, in addition to an optimized RAAS blockade, reduced proteinuria in 153 IgA nephropathy patients. 21 This effect is translated to a reduced risk of progression to ESKD. TRF-budesonide has the potential to become the first specific treatment for IgA nephropathy targeting intestinal mucosal immunity upstream of disease manifestation.
CONCLUSION
In conclusion, serum levels of Gd-IgA1 and Gd-IgA1-specific antibodies are elevated in most IgA nephropathy patients. In immunofluorescence, Gd-IgA1 was co-localized with IgA in the glomeruli of this disease. The TSP therapy is considered to be effective for patients with IgA nephropathy based on basic examinations. However, there are some controversial results of the treatments in this disease. Our patients have improved proteinuria and haematuria levels, and have maintained renal functions without steroids, using TSP therapy or RAAS inhibitors over long-term observation (about 20 years) (unpublished data). Thus, further clinical trials using current or new drugs are needed to determine the indication of treatments in patients with IgA nephropathy.
